Diltiazem Interactions

Negative chronotrope. Potentiates electrophysiologic and hemodynamic effects resulting in bradycardia, sinus arrest, and AV block.

Source: NLP:amiodarone hydrochloride

Calcium antagonist that depresses myocardium and inhibits AV conduction; use with care when combined with bisoprolol fumarate.

Source: NLP:bisoprolol fumarate

Moderate CYP3A inhibitor; when combined with a CYP2C9 inhibitor, will likely lead to large increases in bosentan plasma concentrations. Co-administration not recommended.

Source: NLP:bosentan

Diltiazem increased buspirone AUC 5.5-fold and Cmax 4-fold; adverse events attributable to buspirone may be more likely during concomitant administration.

Source: NLP:buspirone hydrochloride

Moderate CYP3A4 inhibitor increases cilostazol exposure. Requires cilostazol dose reduction to 50 mg twice daily.

Source: NLP:cilostazol

Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported with clonidine and diltiazem concomitantly.

Source: NLP:clonidine

Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported with concomitant use of clonidine and diltiazem.

Source: NLP:clonidine hydrochloride

Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported with concurrent use of clonidine and diltiazem.

Source: NLP:clonidine transdermal system

Moderate or strong CYP3A4 inhibitor; reduce EMFLAZA dose to one third of recommended dosage when used concomitantly.

Source: NLP:deflazacort

Hypotension risk with concomitant erythromycin use. CYP3A4-metabolized calcium channel blocker.

Source: NLP:erythromycin

Do not exceed 10 mg/10 mg ezetimibe and simvastatin tablets daily due to increased myopathy risk.

Source: NLP:ezetimibe and simvastatin

Heart rate-slowing calcium channel blocker. Concomitant use during fingolimod initiation may result in severe bradycardia or heart block.

Source: NLP:fingolimod

Heart rate-slowing calcium channel blocker. Concomitant use during fingolimod initiation may cause severe bradycardia or heart block. Consider switching.

Source: NLP:fingolimod hcl

Increases risk of myopathy/rhabdomyolysis, particularly with higher doses of lovastatin.

Source: NLP:lovastatin

Calcium channel blocker slows atrioventricular conduction and decreases heart rate; concomitant use with metoprolol increases bradycardia risk.

Source: NLP:metoprolol succinate

Calcium channel blocker that slows atrioventricular conduction and decreases heart rate; concomitant use with metoprolol increases risk of bradycardia.

Source: NLP:metoprolol succinate er tablets

Concomitant use increases risk of bradycardia due to additive negative chronotropic effects.

Source: NLP:metoprolol tartrate

Calcium channel blocker that slows atrioventricular conduction; concomitant use with metoprolol can increase risk of bradycardia.

Source: NLP:metoprolol tartrate and hydrochlorothiazide

Calcium channel blocker that may cause excessive reductions in heart rate, blood pressure, and cardiac contractility.

Source: NLP:nebivolol

Calcium channel blocker may cause excessive reductions in heart rate, blood pressure, and cardiac contractility.

Source: NLP:nebivolol hydrochloride

Coadministration in cardiac disease patients associated with bradycardia, hypotension, high degree heart block, and heart failure.

Source: NLP:propranolol hydrochloride

Diltiazem significantly decreases quinidine clearance and increases half-life, requiring monitoring of quinidine levels.

Source: NLP:quinidine gluconate

Calcium channel blocker that increases risk of myopathy and rhabdomyolysis. Do not exceed simvastatin 10 mg daily.

Source: NLP:simvastatin

Calcium channel blocker; concomitant use increases risk of bradycardia and hypotension.

Source: NLP:sotalol hydrochloride

Possible drug interaction with alprazolam based on clinical studies in other benzodiazepines. Caution recommended during coadministration.

Source: NLP:alprazolam

Co-administration resulted in 60% increase in amlodipine systemic exposure in elderly hypertensive patients. Monitor for symptoms of hypotension and edema.

Source: NLP:amlodipine besylate

Calcium antagonist that may depress myocardium and inhibit AV conduction. Use with caution when combined with bisoprolol.

Source: NLP:bisoprolol fumarate and hydrochlorothiazide

CYP3A4 inhibitor that increases carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustment may be required.

Source: NLP:carbamazepine

Calcium channel blocker may affect ECG and/or blood pressure when used with carvedilol.

Source: NLP:carvedilol

Calcium channel blocker that may affect ECG and/or blood pressure when used with carvedilol.

Source: NLP:carvedilol phosphate

Increases cyclosporine concentrations via CYP3A4 inhibition. Dosage adjustment essential.

Source: NLP:cyclosporine

Increases digoxin serum concentration by 20%. Requires monitoring and dose adjustment.

Source: NLP:digoxin

Moderate to strong CYP3A4 inhibitor can increase plasma concentrations of estrogen or progestin or both.

Source: NLP:drospirenone and ethinyl estradiol

Moderate or strong CYP3A4 inhibitor that can increase plasma concentrations of estrogen or progestin or both.

Source: NLP:drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium

Moderate CYP3A4 inhibitor that can increase plasma concentrations of estrogen or progestin.

Source: NLP:drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium

Significant CYP3A inhibitor; estazolam should be used with caution and appropriate dosage reduction may be needed.

Source: NLP:estazolam

Moderate CYP3A4 inhibitor. No dosing adjustments recommended in the presence of this drug.

Source: NLP:fesoterodine fumarate

Bradycardia with coadministration.

Source: NLP:fluvoxamine maleate

Moderate CYP3A4 inhibitor that increases ivabradine plasma concentrations. Avoid concomitant use.

Source: NLP:ivabradine

Concomitant use can increase the risk of bradycardia or hypotension due to additive effects on atrioventricular conduction and heart rate.

Source: NLP:labetalol hydrochloride

Moderate CYP3A4 inhibitor that increases lurasidone exposure; dose should be reduced to half.

Source: NLP:lurasidone hydrochloride

Concomitant use increases risk of bradycardia due to combined negative chronotropic effects.

Source: NLP:metoprolol

Inhibits P450-3A4 enzyme system, increasing midazolam half-life from 5 to 7 hours and prolonging sedation.

Source: NLP:midazolam

Inhibits P450-3A4 enzyme system, increasing midazolam half-life from 5 to 7 hours, resulting in prolonged sedation.

Source: NLP:midazolam hydrochloride

Moderate CYP3A inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.

Source: NLP:naldemedine

Concomitant use can potentiate electrophysiologic and hemodynamic effects, resulting in bradycardia, sinus arrest, and AV block.

Source: NLP:nexterone (amiodarone hci)

CYP3A inhibitor that increases nifedipine AUC by factors of 2.2 to 3.1 and C max by factors of 1.7 to 2.0. Caution should be exercised and dose reduction of nifedipine considered.

Source: NLP:nifedipine

Moderate CYP3A4 inhibitor and calcium channel blocker that may increase nimodipine plasma concentration and blood pressure lowering effect. Blood pressure monitoring and dose reduction of nimodipine may be necessary.

Source: NLP:nimodipine

Significantly decreases quinidine clearance and increases quinidine half-life.

Source: NLP:quinidine sulfate tablet

CYP3A inhibitor that increases ranolazine exposure. Limit ranolazine to 500 mg twice daily.

Source: NLP:ranolazine

Weak/moderate CYP3A4/P-gp inhibitor that may increase sirolimus concentrations. Monitor and adjust dosage as needed.

Source: NLP:sirolimus

Moderate CYP3A4 inhibitor that may increase silodosin concentration. Monitor patients for adverse events.

Source: NLP:silodosin

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Source: NLP:suvorexant

Mild or moderate CYP3A inhibitor calcium channel blocker that may affect tacrolimus concentrations. Monitor tacrolimus whole blood trough concentrations.

Source: NLP:tacrolimus

Data from clinical studies of similar benzodiazepines suggest possible drug interaction with triazolam. Caution recommended.

Source: NLP:triazolam

Moderate CYP3A4 inhibitor. No dosing adjustments recommended with darifenacin.

Source: NLP:darifenacin

Moderate CYP3A4 inhibitor; no dosing adjustments recommended.

Source: NLP:darifenacin hydrobromide

Decreases dutasteride clearance and increases dutasteride exposure, but this change is not clinically significant and no dose adjustment is recommended.

Source: NLP:dutasteride

CYP3A inhibitor not expected to have significant effect on prasugrel active metabolite pharmacokinetics.

Source: NLP:prasugrel

Too little experience with coadministration of flecainide acetate and diltiazem to recommend concomitant use.

Source: NLP:flecainide acetate